🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

OXiGENE Gains On Phase-2 Data

Published 05/24/2016, 10:06 AM
Updated 05/14/2017, 06:45 AM
OTLC
-

OXiGENE Inc (NASDAQ:OXGN) is having an incredible day, and for good reason. The company released data from a recent Phase 2 study, and that data was overwhelmingly positive. Today, we'll talk about the data released from the Phase-2 study, how the market reacted to the news, and what we can expect to see from OXGN moving forward.

OXGN Releases Incredibly Positive Data

The company has been working on combination vascular targeted therapies for women with recurrent ovarian cancer. According to the announcement, the Phase-2 study looking into the treatment met its primary endpoint. OXGN was able to demonstrate a statistically significant improvement in progression-free survival in patients receiving the CA4P combination compared to the control. In a statement, OXGN CEO and President, William D. Schwieterman, M.D., had the following to offer...

We are very pleased that the data from the GOG-0186I study are now available for the medical community... The initial results showing an overall survival benefit for CA4P-treated patients potentially signify a much needed therapeutic advance for women with recurrent ovarian cancer, and we look forward to conducting additional analyses on this important outcome as the data mature.

How The Market Reacted To The News

As investors, one of the first things we learn is that the news moves the market. When positive news is released with regard to a publicly traded company, we can expect to see gains in the value of the stock associated with the company as a result. Adversely, when negative news is released with regard to a publicly traded company, we can expect to see declines. The news that was released surrounding OXiGENE was overwhelmingly positive. So naturally, we're seeing strong gains in the value of the stock today. Currently (9:50), OXGN is trading at $0.91 per share after a gain of $0.35 per share or 62.63% thus far today.

What We Can Expect To See Moving Forward

Moving forward, I have an overwhelmingly bullish opinion of what we can expect to see from OXGN. While the company is in the trial phase of development, it is showing that it is coming out with great things. The news with regard to recurrent ovarian cancer is overwhelmingly positive. If this treatment pans out in the long run, chances are that it will lead to strong revenue, great profit, and ultimately growth in the value of the stock moving forward. Given the data that has been released with regard to the treatment thus far, OXiGENE is obviously on the right track. All in all, things are looking good for the stock moving forward.

Original post

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.